People · Operator
Named in public records as an officer, director or promoter · active 2015–2020 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Orexigen Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $274.6M | $1.8B | 2015 |
| Chinook Therapeutics U.S., Inc. | — | Biotechnology | Series D+ | $180.0M | $4.5B | 2020 |
Preston Klassen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Preston Klassen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 1 | 13 |
| Srinivas Akkaraju | 1 | 10 |
| Brian H. Dovey | 1 | 7 |
| Thomas Lynch | 1 | 7 |
| Louis C. Bock | 1 | 7 |
| Lota S Zoth | 1 | 4 |
| Jeremy Caldwell | 1 | 4 |
| Andrew King | 1 | 3 |
| Sam Hall | 1 | 3 |
| Joseph Hagan | 1 | 2 |
| Paul Eisenberg | 1 | 2 |
| Srini Akkaraju | 1 | 2 |
| Patrick J. Mahaffy | 1 | 2 |
| Wendy L Dixon | 1 | 2 |
| Peter Flynn | 1 | 1 |
| Eckard S Weber | 1 | 1 |
| Peter K Honig | 1 | 1 |
| Michael Narachi | 1 | 1 |
| David J Endicott | 1 | 1 |
| Thomas Cannell | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.